Please assess the completion status of the following clinical trial:

Trial Title: Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria - Transplant Recipients:~* Age less than or equal to 21 years.~* Does not have a suitable MSD or volunteer MUD available in the necessary time for stem cell donation.~* Has a suitable single haplotype matched (≥ 3 of 6) and family member donor.~* High risk hematologic malignancy.~* If prior CNS leukemia, it must be treated and in CNS CR~* Does not have any other active malignancy other than the one for which this HCT is indicated.~* No prior allogeneic HCT, and no autologous HCT within the previous 12 months.~* Patient must fulfill pre-transplant evaluation~Inclusion Criteria - Haploidentical Donor:~* At least single haplotype matched (≥ 3 of 6) family member~* At least 18 years of age.~* HIV negative.~* Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female).~* Not breast feeding.~* Regarding eligibility, is identified as either: (1) Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR (2) Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Transplant Recipients (Type: EXPERIMENTAL): Participants undergo a preparative regimen of total lymphoid irradiation, fludarabine, cyclophosphamide, fludarabine, thiotepa, melphalan, and mycophenolate mofetil, followed by HPC,A infusion and TC-NK infusion. They also receive G-CSF and mesna.~Cells for infusion are prepared using the CliniMACS System.

Based on this trial design, predict the completion outcome and termination type (if applicable).